Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M F Stevens

Showing results (51-60 of 123) with videos related to

Pageof 13
Sort By:
Anti-Cancer Drug Design|February 1, 1990
Anti-tumour imidazotetrazines. Part XXI. Mitozolomide and temozolomide: probes for the major groove of DNAA S Clark, M F Stevens, C E Sansom, et al.
Anti-Cancer Drug Design|April 1, 1995
Structural studies on bioactive compounds. Part 27. Chemistry of the immunomodulatory agent bropirimineM F Stevens, G U Baig, E N Gate, et al.
Journal of Medicinal Chemistry|July 27, 2001
Structural studies on bioactive compounds. 34. Design, synthesis, and biological evaluation of triazenyl-substituted pyrimethamine inhibitors of Pneumocystis carinii dihydrofolate reductaseD C Chan, C A Laughton, S F Queener, et al.
Anti-Cancer Drug Design|April 19, 2002
Investigations on the biological properties of the lipophilic DHFR-inhibitory benzoprims reveal non-folate modes of action and opportunities for anti-cancer drug designK A Croughton, C S Matthews, R J Griffin, et al.
Journal of Medicinal Chemistry|November 1, 1989
Structural studies on bioactive compounds. 8. Synthesis, crystal structure, and biological properties of a new series of 2,4-diamino-5-aryl-6-ethylpyrimidine dihydrofolate reductase inhibitors with in vivo activity against a methotrexate-resistant tumor cell lineR J Griffin, M A Meek, C H Schwalbe, et al.
The Journal of Pharmacy and Pharmacology|December 1, 1979
The biological and chemical properties of 4-azidobenzenesulphonamide ('azidosulphanilamide') [proceedings]E A Bliss, T B Brown, M F Stevens, et al.
Biochemical Pharmacology|January 1, 1981
Studies of the mode of action of antitumour triazenes and triazines-II. Investigation of the selective toxicity of 1-aryl-3,3-dimethyltriazenesA Gescher, J A Hickman, R J Simmonds, et al.
The Journal of Pharmacy and Pharmacology|December 1, 1978
alpha-Hydroxylated triazenes: potential active metabolites of anti-tumour dimethyltriazenes [proceedings]M F Stevens, A Gescher, J A Hickman, et al.
British Journal of Anaesthesia|June 24, 2009
Incidental recognition of an aspirated tablet in an oesophagectomized patientS Braun, R Werdehausen, T Bothur, et al.
DNA Repair|December 4, 2014
The G-quadruplex-stabilising agent RHPS4 induces telomeric dysfunction and enhances radiosensitivity in glioblastoma cellsF Berardinelli, S Siteni, C Tanzarella, et al.
Pageof 13

Showing results (51-60 of 123) with videos related to

Sort By:
Pageof 13
Anti-Cancer Drug Design|February 1, 1990
Anti-tumour imidazotetrazines. Part XXI. Mitozolomide and temozolomide: probes for the major groove of DNAA S Clark, M F Stevens, C E Sansom, et al.
Anti-Cancer Drug Design|April 1, 1995
Structural studies on bioactive compounds. Part 27. Chemistry of the immunomodulatory agent bropirimineM F Stevens, G U Baig, E N Gate, et al.
Journal of Medicinal Chemistry|July 27, 2001
Structural studies on bioactive compounds. 34. Design, synthesis, and biological evaluation of triazenyl-substituted pyrimethamine inhibitors of Pneumocystis carinii dihydrofolate reductaseD C Chan, C A Laughton, S F Queener, et al.
Anti-Cancer Drug Design|April 19, 2002
Investigations on the biological properties of the lipophilic DHFR-inhibitory benzoprims reveal non-folate modes of action and opportunities for anti-cancer drug designK A Croughton, C S Matthews, R J Griffin, et al.
Journal of Medicinal Chemistry|November 1, 1989
Structural studies on bioactive compounds. 8. Synthesis, crystal structure, and biological properties of a new series of 2,4-diamino-5-aryl-6-ethylpyrimidine dihydrofolate reductase inhibitors with in vivo activity against a methotrexate-resistant tumor cell lineR J Griffin, M A Meek, C H Schwalbe, et al.
The Journal of Pharmacy and Pharmacology|December 1, 1979
The biological and chemical properties of 4-azidobenzenesulphonamide ('azidosulphanilamide') [proceedings]E A Bliss, T B Brown, M F Stevens, et al.
Biochemical Pharmacology|January 1, 1981
Studies of the mode of action of antitumour triazenes and triazines-II. Investigation of the selective toxicity of 1-aryl-3,3-dimethyltriazenesA Gescher, J A Hickman, R J Simmonds, et al.
The Journal of Pharmacy and Pharmacology|December 1, 1978
alpha-Hydroxylated triazenes: potential active metabolites of anti-tumour dimethyltriazenes [proceedings]M F Stevens, A Gescher, J A Hickman, et al.
British Journal of Anaesthesia|June 24, 2009
Incidental recognition of an aspirated tablet in an oesophagectomized patientS Braun, R Werdehausen, T Bothur, et al.
DNA Repair|December 4, 2014
The G-quadruplex-stabilising agent RHPS4 induces telomeric dysfunction and enhances radiosensitivity in glioblastoma cellsF Berardinelli, S Siteni, C Tanzarella, et al.
Pageof 13